Results 121 to 130 of about 1,377,243 (284)

Sulfonylurea-induced hypoglycaemia: use of octreotide.

open access: yes, 2009
Sulfonylurea compounds are commonly used to treat type 2 diabetes mellitus. The case of an old alcoholic addicted diabetic patient treated with gliquidone developing recurrent and prolonged hypoglycaemias refractory to dextrose administration is related.
Hanchard, B   +2 more
core  

Free radical reaction of fluorine containing compounds [PDF]

open access: yes, 1989
This thesis is concerned with the free-radical addition of oxygen containing compounds of the adducts produced. Free-radical additions of ether compounds to fluoroalkenes have been done by previous workers and the chemistry of some of these adducts has ...
Abu-Nasrieh, Omar M.
core  

Sulfonylurea prescriptions overall and in subjects 65 or older.

open access: yes, 2019
SU: sulfonylurea.
Amanda K. Kitten (7244921)   +3 more
core   +1 more source

Serum‐derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus

open access: yesJournal of Diabetes Investigation, EarlyView.
This study evaluated serum miRNAs as biomarkers in adult patients with SPIDDM. Serum miRNAs were measured at the time of SPIDDM (probable) diagnosis, and miR‐150‐5p was inversely associated with CPI at the last outpatient visit, suggesting its potential utility for predicting subsequent insulin secretory decline.
Hideyuki Okuma   +4 more
wiley   +1 more source

SEPARATION OF SULFONYLUREA METABOLITES IN WATER BY CAPILLARY ELECTROPHORESIS

open access: yes, 1995
The potential of capillary electrophoresis (CE) for the separation and detection of the metabolites of nine sulfonylurea herbicides in aqueous solution was evaluated.
VICARI A, BONETTI A, DINELLI G
core   +1 more source

Association of glycation gap with hypoglycemia CGM indices, diabetic complications, and quality of life in Japanese type 2 diabetes patients

open access: yesJournal of Diabetes Investigation, EarlyView.
The difference between HbA1c and estimated A1c (eA1c) was defined as the GGap. The strong association of high GGap with CGM‐based hypoglycemic indices in type 2 diabetes is evident. The large GGap values, relying solely on HbA1c values during treatment, may increase the risk of hypoglycemia in patients with T2DM.
Satomi Sonoda   +13 more
wiley   +1 more source

Effects of esaxerenone add‐on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

open access: yesJournal of Diabetes Investigation, EarlyView.
ABSTRACT Aims Residual albuminuria remains a major clinical challenge in patients with type 2 diabetes mellitus and hypertension despite renin–angiotensin system inhibitor therapy. Esaxerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduces albuminuria; however, its effects on oxidative stress remain unclear.
Makoto Ohara   +9 more
wiley   +1 more source

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

open access: yesJournal of Diabetes Investigation, EarlyView.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura   +6 more
wiley   +1 more source

Novel chemotype NLRP3 inhibitors that target the CRID3-binding pocket with high potency

open access: yesLife Science Alliance
The NLRP3 inflammasome drives various diseases. Here, we describe novel potent and selective NLRP3-targeted inhibitors to bolster pharmacological studies and development of NLRP3-targeted therapies.
Lieselotte Vande Walle   +6 more
doaj   +1 more source

Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin

open access: yes, 2016
Xiaomei Peng, Dingfeng Jiang, Dongju Liu, Oralee J Varnado, Jay P Bae Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, IN, USA Background: Metformin is an oral antidiabetic drug (OAD) widely used as first-line ...
Peng X   +4 more
core  

Home - About - Disclaimer - Privacy